Actelion Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actelion Pharmaceuticals Ltd.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.
Health And Wellness Executive Decisions: NIH ODS Director, B+L Consumer Chief, Herbalife, More
Army Institute Performance Division physiologist leads NIH ODS; Ferris heads B+L consumer products; medical director For HumanN supplements; and Herbalife scores Ronaldo sponsorship extension.
Claritin Liqui-Gels' Label ‘Refresh’ Loses Blue Sky
Changes replace blue background used across Claritin line with white above navy blue waves. Brand’s still printed in white text, but in letters with blue shadow; other package-front text is in red or green instead of yellow.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
- Other Names / Subsidiaries
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.